The level of blood thrombogenicity was not elevated in stable patients with disrupted coronary plaque  by Ueda, Yasunori et al.
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Background:  Although  extremely  high  blood  thrombogenicity  has  been  reported  in patients  with  acute
myocardial  infarction,  it has  not  been  clariﬁed  if  the  increased  blood  thrombogenicity  is  a  cause  of  acute
myocardial  infarction  or  a mere  result  induced  by  thrombus  formation  at the  disrupted  plaque.  Therefore,
we examined  if blood  thrombogenicity  is extremely  increased  as in acute  myocardial  infarction  patients
when  disrupted  plaque  is present  in patients  with  stable  coronary  artery  disease.
Methods and results:  Consecutive  patients  (n =  38) with  stable  coronary  artery  disease  who  received
angioscopic  examination  were  included.  Patients  were  divided  into  two  groups  according  to presence
or absence  of disrupted  plaque  that  accompanied  thrombus.  Blood  thrombogenicity  was  evaluated  by
blood  vulnerability  index  and compared  between  the  patients  with  and without  disrupted  plaque.  Amonghrombus
lood thrombogenicity
lood vulnerability index
38  study  patients,  16  had  disrupted  plaque  and  22  did not.  Blood  vulnerability  index  was  not  different
between  the patients  with  and  without  disrupted  plaque  (2395  ±  612  vs.  3013  ±  1476,  p  =  0.12). Multi-
variate  analysis  revealed  no signiﬁcant  association  between  blood  vulnerability  index  and  the  presence
of disrupted  plaque.
Conclusion: The  presence  of disrupted  plaque,  in comparison  with  its  absence,  was  not  associated  with
higher  blood  thrombogenicity  evaluated  by blood  vulnerability  index.
3  Jap©  201
ntroduction
Silent plaque disruptions are not rare ﬁndings in the coronary
rteries, and a small percentage of disrupted plaques will actually
ause acute myocardial infarction [1–5]. Therefore, some additional
actors should be required for the disrupted plaques to cause acute
yocardial infarction [6]. Increase in the blood thrombogenicity
ay  be a potential factor and high blood thrombogenicity has been
eported in patients with acute myocardial infarction [7]. How-
ver, it is not clear if the increased blood thrombogenicity really
lays an important role as a cause of acute myocardial infarction
r if it is induced by thrombogenesis at the disrupted plaque com-
only found at culprit lesions of myocardial infarction. Therefore,
e examined consecutive patients with stable coronary artery dis-
ase, dividing them into those with and without disrupted plaque,
nd compared the level of blood thrombogenicity between them to
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clarify if the presence of disrupted plaque is associated with higher
blood thrombogenicity.
Methods
Study patients
Consecutive patients (n = 38) with stable coronary artery dis-
ease who  received percutaneous coronary intervention (PCI) and
angioscopic examination were included. Exclusion criteria were
distal lesion location, vessel diameter <2.0 mm,  and severe vessel
tortuosity, which were not suitable for angioscopic examination.
Catheterization was performed by femoral, brachial, or radial artery
approach using a 6 or 7Fr sheath and catheters.
Patients were divided into two  groups according to presence
or absence of disrupted plaque at the target lesion of PCI. Blood
thrombogenicity was  evaluated by blood vulnerability index [7]
measured before the administration of heparin and were compared
between the patients with and without disrupted plaque.
All patients who  were not taking dual antiplatelet ther-
apy received a loading dose of aspirin 200 mg  and clopidogrel
300 mg  on the day before catheterization. Intravenous heparin was
vier Ltd. All rights reserved.
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dministered after the measurement of blood vulnerability index
mmediately before catheterization. Glycoprotein IIb/IIIa inhibitors
ere not used for anyone, because they were not approved in Japan.
Hypertensive patients were deﬁned as patients with blood
ressure >140/90 mmHg  or those already taking anti-hypertensive
rugs. Diabetic patients were deﬁned as patients with fasting blood
lucose >126 mg/dl or those already taking oral drugs for diabetes
ellitus or receiving insulin therapy. This study was approved by
he Osaka Police Hospital Ethical Committee. Written informed
onsent was obtained from all the enrolled patients.
ngioscopic examination and evaluation
The angioscope RX-3310A & MV-5010A (Machida, Tokyo, Japan)
nd optic ﬁber DAG-2218LN (Machida, Tokyo, Japan) were used.
he angioscopic observation of PCI target lesions was  done while
lood was cleared away from view by the injection of 3% dextran-
0 as we have previously reported [8]. Yellow color grade of the
esions were classiﬁed into 3 grades (1, slight yellow; 2, yellow; 3,
ntense yellow) compared with standard colors as we have pre-
iously reported [9,10]. Thrombus was deﬁned as white or red
aterial that had cotton-like or ragged appearance or that pre-
ented fragmentation with or without protrusion into the lumen or
dherent to the luminal surface. The plaques with thrombus were
eﬁned as disrupted plaques. For each target lesion, presence or
bsence of disrupted plaque was determined. Two specialists of
ngioscopy evaluated the angioscopic images blinded to patients’
haracteristics. In case of disagreement, a third reviewer served
s an arbitrator. The inter- and intra-observer reproducibility for
he interpretation of angioscopic images was good for plaque color
kappa = 0.77 and 0.92) and for thrombus (kappa = 0.79 and 1.00),
espectively.valuation of blood thrombogenicity
Thrombogenic potential of whole blood was evaluated by blood
ulnerability index calculated from the volume–time curve of
able 1
atients’ characteristics.
A
No. of patients 3
Male gender, n (%) 3
Age,  years 6
Risk  factors, n (%)
Diabetes mellitus 1
Hypertension 3
Hypercholesterolemia 3
Current smoking 1
Body  mass index 2
Lipid  proﬁle, mg/dL
Total cholesterol 1
High  density lipoprotein cholesterol 4
Triglyceride 1
Low  density lipoprotein cholesterol 1
Hemoglobin A1c 6
Creatinine, mg/dL 1
C-reactive protein, mg/dL 0
Hemoglobin, mg/dL 1
Target vessel, n (%) 
Left  anterior descending coronary artery 1
Left  circumﬂex coronary artery 1
Right  coronary artery 2
Medications, n (%)
Statin 2
Aspirin 3
Clopidogrel/ticlopidine 1
Angiotensin receptor blocker/angiotensin converting enzyme inhibitor 2
-Blocker 1
ontinuous data are presented as mean ± SD.logy 61 (2013) 326–329 327
whole blood run through the micro-channels in a commercially
available device Micro-Channel Array Flow Analyzer (MC-FAN,
MC Laboratory, Tokyo, Japan) as previously reported [7]. The
method of obtaining blood samples and measuring blood vul-
nerability index was exactly the same as in the previous report.
Brieﬂy, blood samples obtained from patients (5 mL  through artery
sheath) were immediately heparinized (5%) and examined by
MC-FAN. Volume–time curve of whole blood run through the
micro-channels up to 100 s or 100 L was  drawn by MC-FAN, and
the area under the curve within 100 s and 100 L was calculated
and deﬁned as blood vulnerability index.
Statistical analysis
Continuous data were presented as mean ± SD. Comparisons
between groups were done by unpaired student t-test or chi-
square test. To determine the signiﬁcant factors associated with
blood vulnerability index, multivariate stepwise linear regression
analysis was  performed including plaque disruption, total choles-
terol, triglyceride, hemoglobin, aspirin, ticlopidine/clopidogrel,
creatinine, C-reactive protein, and current smoking as indepen-
dent variables. To determine the signiﬁcant factors associated
with plaque disruption, multivariate stepwise logistic regres-
sion analysis was performed including blood vulnerability index,
hypertension, diabetes mellitus, current smoking, number of
antiplatelet drugs, statins, total cholesterol, low-density lipopro-
tein cholesterol, triglyceride, creatinine, and C-reactive protein as
independent variables. A p-value <0.05 was regarded as statisti-
cally signiﬁcant. Analysis was performed with SPSS version 16.0J
for Windows (SPSS Inc., Chicago, IL, USA).
ResultsAmong 38 study patients, 16 had disrupted plaque and 22 did
not. There was  no difference in the patients’ background, except
that current smoking was  more frequent in the patients with dis-
rupted plaque than in those without (Table 1). The yellow color
ll Disrupted Non-disrupted p value
8 16 22
0 (79) 14 (88) 16 (73) 0.42
9 ± 7 69 ± 6 69 ± 8 0.92
7 (45) 6 (38) 11 (50) 0.52
3 (87) 12 (75) 21 (96) 0.14
0 (79) 12 (75) 18 (82) 0.69
3 (34) 9 (56) 4 (18) 0.02
5 ± 4 24 ± 3 25 ± 5 0.34
76 ± 34 183 ± 39 170 ± 29 0.25
6 ± 15 51 ± 16 43 ± 13 0.11
65 ± 126 146 ± 106 179 ± 140 0.44
04 ± 30 110 ± 34 99 ± 25 0.26
.0 ± 1.1 5.9 ± 1.3 6.1 ± 0.9 0.69
.0 ± 0.3 0.9 ± 0.4 1.0 ± 0.3 0.52
.73 ± 2.6 0.13 ± 0.15 1.16 ± 3.4 0.24
4 ± 2 14 ± 1 14 ± 2 0.29
0.46
6 (42) 7 (44) 9 (41)
 (3) 1 (6) 0 (0)
1 (55) 8 (50) 13 (59)
2 (59) 8 (50) 14 (64) 0.51
4 (90) 15 (94) 19 (86) 0.62
8 (47) 6 (38) 12 (55) 0.34
4 (63) 8 (50) 16 (73) 0.18
5 (40) 4 (25) 11 (50) 0.18
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Table 3
Factors associated with plaque disruption: multivariate stepwise logistic regression
analysis.
Odds ratio (95% conﬁdence interval) p value
Current smoking 5.7 (1.3–25.0) 0.01
Independent variables included in the model: blood vulnerability index, hyperten-28 Y. Ueda et al. / Journal of 
rade of the target lesions was signiﬁcantly higher (1.9 ± 0.8 vs.
.1 ± 1.1, p = 0.02) in the patients with disrupted plaque than in
hose without.
Blood vulnerability index (2395 ± 612 vs. 3013 ± 1476, p = 0.12)
as not different between the patients with and without disrupted
laque (Fig. 1). Multivariate stepwise linear regression analysis
evealed that C-reactive protein and creatinine were signiﬁcantly
ssociated with blood vulnerability index but the presence of dis-
upted plaque was not (Table 2). Multivariate stepwise logistic
egression analysis revealed that current smoking was signiﬁcantly
ssociated with plaque disruption but blood vulnerability index
as not (Table 3).
iscussionAccording to the results of present study, presence of disrupted
laque was not signiﬁcantly associated with a higher level of blood
ulnerability index. Therefore, the presence of disrupted plaque
hould not be the major mechanism that increases blood thrombo-
ig. 1. Blood vulnerability index comparing patients with and without disrupted
laque. Blood vulnerability index (2395 ± 612 vs. 3013 ± 1476, p = 0.12) was not dif-
erent between the patients with and without disrupted plaque. Mean with SD (A)
nd individual data (B) were presented.
able 2
actors associated with blood vulnerability index: multivariate stepwise linear
egression analysis.
B (95% conﬁdence interval) p value
C-reactive protein 158(19–298) 0.02
Creatinine 1159(22–2297) 0.04
ndependent variables included in the model: plaque disruption, total cholesterol,
riglyceride, hemoglobin, aspirin, ticlopidin/clopidogrel, creatinine, C-reactive pro-
ein,  and current smoking.sion,  diabetes mellitus, current smoking, number of antiplatelet drugs, statin, total
cholesterol, LDL cholesterol, triglyceride, creatinine, and C-reactive protein.
genicity to the extremely high level detected in acute myocardial
infarction patients [7].
We have previously reported [7] that high blood thrombo-
genicity evaluated by blood vulnerability index was signiﬁcantly
associated with acute myocardial infarction and furthermore with
poor initial thrombolysis in myocardial infarction ﬂow grade. This
high level of blood vulnerability index in the acute myocardial
infarction patients decreased signiﬁcantly at 2 weeks suggesting
a temporal increase of blood vulnerability index only in the acute
phase. Blood vulnerability index is a parameter of whole blood
thrombogenicity that is determined by multiple factors including
platelet function and coagulation factors [11,12].
Increased blood vulnerability index might be a cause or a result
of acute myocardial infarction. Because platelet aggregation at one
lesion is known to lead to systemic hyper-activation of circulating
platelets, increased blood vulnerability index might occur as the
result of plaque disruption and thrombus formation at the culprit
lesion of myocardial infarction. On the other hand, if it is a cause of
acute myocardial infarction onset, we can open a new window to
the new strategy of preventing acute myocardial infarction onset.
The antithrombotic drugs commonly used now (aspirin and ticlo-
pidine/clopidogrel) have been reported to have a limited effect in
acute myocardial infarction patients [7], which is consistent with
the fact that those drugs cannot prevent the onset of acute myocar-
dial infarction adequately. Therefore, the ideal drugs to prevent the
onset of acute myocardial infarction may  be those that can prevent
the acute increase of blood vulnerability index without reducing
the basal thrombogenic potential of blood.
According to the multivariate analysis, C-reactive protein and
creatinine but not presence of disrupted plaque was  signiﬁcantly
associated with blood vulnerability index, and current smoking but
not blood vulnerability index was signiﬁcantly associated with the
presence of disrupted plaque. Therefore, no association was  sug-
gested between the presence of disrupted plaque and high blood
vulnerability index. Furthermore, the higher acute coronary syn-
drome (ACS) risk in the patients with higher C-reactive protein or
higher creatinine may  possibly be due to the higher blood throm-
bogenicity in those patients.
Although no patients without ACS in our previous study [7] had
blood vulnerability index >4000, ﬁve patients without disrupted
plaque in the present study had high (>4000) blood vulnerabil-
ity index (4159, 4617, 5299, 5472, and 7162), but only one of the
patients with disrupted plaque had a slightly high value (4148). A
plausible explanation would be that those patients regardless of
having highly thrombogenic blood did not have acute myocardial
infarction because they did not have thrombogenic lesion (dis-
rupted plaque), and that the patients with disrupted plaque did
not suffer acute myocardial infarction because they had blood of
relatively low thrombogenic potential. The combination of throm-
bogenic lesion and thrombogenic blood would be required for the
coronary artery to be occluded by thrombus.
Although it is difﬁcult to evaluate the angioscopic image quan-
titatively, we  have the impression that the disrupted plaques in
ACS patients have a larger amount of thrombus than in stable
patients both in culprit and non-culprit segments. This might be
the result of higher blood thrombogenicity in ACS patients than in
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table patients. Multiple plaque disruptions and their healing pro-
ess both in culprit and non-culprit segments have been reported
13]. Therefore, the mechanism for the onset of acute myocardial
nfarction can be speculated as a hypothesis. First of all, the vulner-
ble plaques are formed as a result of atherosclerosis. Vulnerable
laques disrupt and form thrombogenic lesions in the coronary
rteries. These thrombogenic lesions remain actively thrombogenic
or a long time. Some of them cause thrombogenic coronary occlu-
ion when blood becomes highly thrombogenic and others heal
nd lose thrombogenic potential. The combination of blood and
esion thrombogenicity determines the amount of thrombus and
hether or not the coronary artery is occluded. The relatively long
ime interval between the formation of thrombogenic lesion and
he onset of acute myocardial infarction has been suggested by
ome previous reports [14,15]. The dynamic change in the blood
hrombogenicity has been reported by circadian changes in platelet
ctivation, which is most activated at around 07:00 h [16]. The
vents of coronary thrombosis, i.e. acute myocardial infarction and
tent thrombosis, are known to have a circadian rhythm occurring
ost frequently at around 07:00 h [17–19]. Muller et al. had already
uggested in 1994 that the occurrence of myocardial infarction in
he morning could result from the synchronization of a number of
otential triggers [20], which has not yet been fully clariﬁed.
The small number of patients in this study is an important
imitation and might cause selection bias; however, none of the
table patients with disrupted plaque had extremely high blood
ulnerability index as detected in the acute myocardial infarction
atients [7]. According to the previous validation studies using
istology as gold standard [21,22], the speciﬁcity, accuracy, and
redictive value of angioscopy to detect disrupted plaque were high
>90%) while its sensitivity was moderate (73%) due to its failure
n detecting small disruptions. However, the speciﬁcity, accuracy,
nd predictive value of angioscopy to detect thrombus were high
>93%) and its sensitivity was excellent (100%). Therefore, the
ngioscopic detection of disrupted plaque deﬁned as the plaques
hat have thrombus would be reliable. The method of measuring
lood vulnerability index has not been adequately evaluated so far
n the mechanisms and factors that inﬂuence the results. How-
ver, this unique method can evaluate the thrombogenic potential
f whole blood by a single parameter. Furthermore, blood vulner-
bility index can show the thrombogenicity of whole blood almost
s it is, because the sample blood is not modiﬁed but is only hep-
rinized before measurement; therefore, it can sensitively reﬂect
he change in the blood thrombogenicity caused by various known
nd unknown factors.
In conclusion, the presence of disrupted plaque, in comparison
ith its absence, was not associated with the higher blood throm-
ogenicity evaluated by blood vulnerability index. Therefore, the
resence of disrupted plaque should not be the major mechanism
hat increases blood thrombogenicity to the extremely high level
etected in acute myocardial infarction patients.
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